Is there a Possible Association between Multiple Myeloma Relapse and Coronavirus Disease 2019 Vaccination? A Case Report

• Published in: Dental research journal 2024-01, Vol.13 (1), p.27-32
• Main Authors: Shirzad-Yazdi, Nasrin, Namdari, Nasrin, Noorani, Anahid, Karimzadeh, Iman
• Format: Article
• Language: English
• Subjects: Biopsy; Cancer vaccines; Case Report; Case reports; coronavirus disease 2019 vaccines; Coronaviruses; COVID-19 vaccines; drug-related adverse reactions; Immunization; Malignancy; Morbidity; Mortality; Multiple myeloma; Patients; Remission
• ISSN: 2319-9644; 1735-3327; 2279-042X; 2008-0255
• DOI: 10.4103/jrpp.jrpp_21_24

Due to the high morbidity and mortality of the coronavirus disease 2019 (COVID-19) in patients with malignancy, the necessity of vaccination in this group of patients became particularly important. Although a large number of studies have reported the safety of COVID-19 vaccination in multiple myeloma (MM) patients, the effect of the COVID-19 vaccine on MM relapse has not yet been reported. Here, we report a case of a possible association between relapse of MM and COVID-19 vaccination with Sinopharm ® , an inactivated virus vaccine, in a patient with MM who has remained in complete remission for about 4 years. The MM relapse in the patient was diagnosed by both clinical findings and laboratory workup including serum protein electrophoresis, bone marrow aspiration, and biopsy. Despite this possible association between COVID-19 vaccination and MM relapse in the patient, given its importance in reducing mortality and having an acceptable safety profile, the COVID-19 vaccine should be administered to all cancer patients. However, careful monitoring and follow-up are recommended in patients with MM after COVID-19 vaccination.